AstraZeneca pulled its Phase 3 volrustomig lung trial at interim review — and released no efficacy data at all. The eVOLVE-Lung02 study tested the PD-1 by CTLA-4 bispecific plus chemotherapy against pembrolizumab plus chemo in first-line PD-L1-low non-small cell lung cancer, and the monitoring committee called both co-primary endpoints unlikely to hit. We unpack what survives in mesothelioma, cervical and head and neck, and why an unpublished failure costs the whole field twice. Also: LEO Pharma's up-to-$435 million acquisition of dersimelagon (MT-7117) from Tanabe Pharma for erythropoietic protoporphyria, and a new study showing gray-market retatrutide isn't matching Eli Lilly's trial results.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
Podden och tillhörande omslagsbild på den här sidan tillhör
BZ Group. Innehållet i podden är skapat av BZ Group och inte av,
eller tillsammans med, Poddtoppen.
